News in brief: Drug company asks for review of Alzheimer's drugs

A formal application for judicial review of the NICE decision on drugs for Alzheimer’s disease has been made by pharmaceutical company Eisai Limited. NICE chief executive Andrew Dillon said: ‘We consider its claim without foundation and it will require us to divert energy and funding from the work we do to support patients and health professionals.’ The Alzheimer’s Society will also challenge the NICE decision in the High Court.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in